Vertex Pharmaceutical
TPS05.5- Maximizing benefits with early CFTR modulator treatment: Lower sweat chloride is associated with improved clinical outcomes in children aged 6 to 11 years
Friday, October 24, 20252:30 PM - 4:00 PM PDT